Revision history of "Search for biomarkers associated with clinical response in children with cancer treated with Celyvir" (Q3154350)

Jump to navigation Jump to search

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

8 October 2024

  • curprev 23:5623:56, 8 October 2024DG Regio talk contribs 70,114 bytes +44 Set a claim value: summary (P836): A nossa equipa de investigação desenvolveu uma nova estratégia de viro-imunoterapia para tumores sólidos infantis refratários: Celyvir, células mesenquimais autólogas (CME) infetadas com um adenovírus oncolítico. Neste projeto pretendemos aumentar o nosso conhecimento sobre as características da terapia que podem atuar como biomarcadores da resposta clínica. Para fazer isto, nós analisaremos os tumores das crianças tratadas, estudando a sua carga de...

7 March 2024

20 December 2023

12 June 2023

10 June 2023

5 September 2022

16 January 2022

17 December 2021

9 December 2021

2 December 2021

  • curprev 17:1017:10, 2 December 2021DG Regio talk contribs 14,800 bytes +2,366 Created claim: summary (P836): Notre équipe de recherche a développé une nouvelle stratégie de viro-immunothérapie pour les tumeurs solides réfractaires de l’enfance: Celyvir, cellules mésenchymiques autologues (CSM) infectées par un adénovirus oncolytique. Dans ce projet, nous visons à accroître nos connaissances sur les caractéristiques de la thérapie qui peut agir comme biomarqueurs de la réponse clinique. Pour ce faire, nous allons analyser les tumeurs des enfants traités...
  • curprev 17:1017:10, 2 December 2021DG Regio talk contribs 12,434 bytes +180 Changed label, description and/or aliases in fr: translated_label

12 October 2021

  • curprev 15:3815:38, 12 October 2021DG Regio talk contribs 12,254 bytes +2,141 Created claim: summary (P836): Our research team has developed a new viro-immunotherapy strategy for refractory childhood solid tumors: Celyvir, autologous mesenchymal cells (MSCs) infected with an oncolytic adenovirus. In this project we aim to increase our knowledge about the characteristics of the therapy that can act as biomarkers of the clinical response. To do this, we will analyse the tumors of the treated children, studying both their load of mutations and the pathway...
  • curprev 15:3815:38, 12 October 2021DG Regio talk contribs 10,113 bytes −2,141 Removed claim: summary (P836): Our research team has developed a new viro-immunotherapy strategy for refractory childhood solid tumors: Celyvir, autologous mesenchymal cells (MSCs) infected with an oncolytic adenovirus. In this project we aim to increase our knowledge about the characteristics of the therapy that can act as biomarkers of the clinical response. To do this, we will analyse the tumors of the treated children, studying both their load of mutations and the pathw...
  • curprev 15:3515:35, 12 October 2021DG Regio talk contribs 12,254 bytes +160 Changed label, description and/or aliases in en: translated_label
  • curprev 15:3515:35, 12 October 2021DG Regio talk contribs 12,094 bytes +2,141 Created claim: summary (P836): Our research team has developed a new viro-immunotherapy strategy for refractory childhood solid tumors: Celyvir, autologous mesenchymal cells (MSCs) infected with an oncolytic adenovirus. In this project we aim to increase our knowledge about the characteristics of the therapy that can act as biomarkers of the clinical response. To do this, we will analyse the tumors of the treated children, studying both their load of mutations and the pathway...

10 October 2021

9 October 2021

8 October 2021